Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.7K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

8.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
8.2K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools.

Clinical pharmacokinetics·2026
Same author

Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease.

Clinical pharmacokinetics·2026
Same author

Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.

British journal of clinical pharmacology·2026
Same author

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Journal of Crohn's & colitis·2026
Same author

A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients.

Infection·2025
Same author

Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same journal

ACG Clinical Guideline: Colonic Diverticulitis.

The American journal of gastroenterology·2026
Same journal

Inter and intra-observer agreement for the LST Classification in Large (>2cm) Colorectal Laterally Spreading Tumours.

The American journal of gastroenterology·2026
Same journal

The Safety and Effectiveness of Early Anti-Tumor-Necrosis-Factor Therapy for Penetrating Crohn's Disease Complications in Children.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: September 2024.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: September 2024.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: September 2024.

The American journal of gastroenterology·2026
See all related articles

Related Experiment Videos

Response to Dai et al

Yannick Hoffert1, Erwin Dreesen

  • 1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

The American Journal of Gastroenterology
|July 16, 2025
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos